Davis, CA – According to filings with the U.S. Securities and Exchange Commission, BCD Bioscience is raising $13,000,010.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Steven Watkins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BCD Bioscience
BCD Bioscience is creating the worlds first broad library of oligosaccharides with diverse natural structures, and linking these structures to their functions as prebiotics and immunomodulators. We are using our technology to develop ingredients and therapies for better human and animal health both alone and in partnership with others. We develop and utilize state-of-the-art analytical procedures to understand the types and distributions of carbohydrates in natural products. Using a proprietary food-grade process, we produce functional oligosaccharides from a diverse collection of sources. We identify the unique abilities of oligosaccharides to modulate the microbiome and immune systems to enhance human health.

To learn more about BCD Bioscience, visit http://www.bcdbio.com/

Contact:
Steven Watkins, Chief Executive Officer
530-400-8155
https://www.linkedin.com/in/steven-watkins-8623195/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved